| Literature DB >> 33212235 |
Mark P Lythgoe1, Jonathan Krell2, Sarah Mahmoud3, Emily C Mills4, Aishwarya Vasudevan4, Philip Savage4.
Abstract
Analysis of new anticancer drugs licensed in the UK found that 44 new therapies were approved from 2015 to 2019. No other 5-year period has produced as many new therapies. Most new drugs are kinase inhibitors (KIs, N=18) and monoclonal antibodies (mAbs, N=16) with only one classical cytotoxic chemotherapy (CC) licensed. The average median treatment duration has risen by 55 days to 318 days (263 days in 2010-2014). Drug costs have escalated; an average treatment course now costs £62 343, compared to £35 383 in 2010-2014. New drugs are delivering significant clinical benefits with longer treatment durations. However, the financial burden is greater, heralding economic challenges for healthcare providers.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33212235 DOI： 10.1016/j.drudis.2020.11.011
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851